QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Kenneth Carwell has lived within a 1-mile area his whole life, but his sphere of influence extends far beyond geographic boundaries. Ken’s educational training is in social work, and his roles and responsibilities throughout his 40-year career focused on…
Is equal access to health care associated with reduced racial and ethnic disparities in outcomes of nonmetastatic castration-resistant prostate cancer? A retrospective cohort study of approximately 13,000 veterans treated in an equal-access healthcare setting was conducted. Patients included in the…
Prostate cancer incidence increased by 3% annually from 2014-2019 after two decades of decline, translating to an additional 99,000 new cases. Future progress in reducing prostate cancer-specific mortality may be curtailed by the rising incidence of prostate cancer which also…
This original investigation aimed at characterizing the long-term outcomes of patients with low-risk prostate cancer (i.e., low-volume and low Gleason grade tumors) receiving active surveillance in a multicenter, protocol-directed cohort. A cohort of over 200 men with favorable-risk prostate cancer…
This study examined whether an annual prostate magnetic resonance imaging (MRI) and potential MRI- guided biopsy are cost-effective compared with a transrectal ultrasonographic (standard) biopsy for men with a positive prostate-specific antigen (PSA) test result. In an economic evaluation, annual…
Percent free prostate-specific antigen (PSA) is a measurement used in prostate cancer screening to provide additional information over and above that provided by the total PSA value alone about the likelihood of prostate cancer. PSA is a protein produced by…
Prostate cancer is a leading cause of cancer-related death, accounting for 288,300 new cases and 34,700 deaths each year. Few consistent modifiable risk factors for prostate cancer have been identified, limiting the scope for primary prevention. In 2012, the United…
The study aimed to determine if incorporating percent-free PSA alongside total PSA could enhance the prediction of clinically significant and fatal prostate cancer risks. Researchers analyzed data from 6,727 men enrolled in the Nationally funded NIH Prostate, Lung, Ovarian, and…
What factors are associated with a shorter time interval to prostate-specific antigen (PSA) failure in nonmetastatic unfavorable-risk prostate cancer? The objective of this study was to evaluate the factors of a short time interval to PSA failure to identify patients…
The study investigated how body mass index (BMI) relates to prostate cancer screening results, incidence, and mortality among men participating in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. This trial included 36,756 men who were regularly screened…
"*" indicates required fields
